Literature DB >> 19620809

[A case of colon cancer with reversible posterior leukoencephalopathy syndrome following 5-FU and oxaliplatin (FOLFOX regime)].

Yasunobu Nagata1, Yasushi Omuro, Tatsu Shimoyama, Eisaku Sasaki, Rumiko Okamoto, Yoshiharu Maeda, Shuji Kishida, Tsuneo Sasaki.   

Abstract

We report a rare case of reversible posterior leukoencephalopathy syndrome (RPLS) induced by 5-FU and oxaliplatin (FOLFOX regime). A 35-year-old woman with ileus was diagnosed with sigmoid cancer Stage IV (T4N4M0P2H0), and excision of the sigmoid colon, and left ureteroureteral anastomosis was performed. Postoperative chemotherapy with FOLFOX4 was performed. Complications of hypertension were seen on day 6, and convulsions on day 11 after chemotherapy. Headache and visual disturbance were also complications. MRI of the brain revealed bilateral high signal intensities of posterior lobes on T2 weighted and FLAIR images without enhancement. The patient was treated with antihypertensive therapy and anticonvulsive therapy. Her symptoms entirely disappeared, including the bilateral posterior lesions on MRI after two weeks. This report would suggest that medical oncologists should be aware that multidrug chemotherapies may increase the risk of fatal neurological complications like RPLS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19620809

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  3 in total

1.  Oxaliplatin-induced posterior reversible encephalopathy syndrome (PRES).

Authors:  Taimoor Khalid Janjua; Muhammad Hassan; Hira Khan Afridi; Naila Anjum Zahid
Journal:  BMJ Case Rep       Date:  2017-10-04

2.  Tacrolimus associated posterior reversible encephalopathy syndrome - a case series and review.

Authors:  Susmitha Apuri; Kristin Carlin; Edward Bass; Phuong Thuy Nguyen; John N Greene
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-02-18       Impact factor: 2.576

3.  Atypical reversible leucoencephalopathy syndrome after bevacizumab/folfox regimen for metastatic colon cancer.

Authors:  Narimane Salmi; Ibrahim Elghissassi; Khadija Bellahammou; Asmaa Lakhdissi; Hind Mrabti; Hassan Errihani
Journal:  Case Rep Oncol Med       Date:  2014-10-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.